Status:

Do Not Prescribe (DNP), Red

Decision Date:

November 2021

Comments

RED: NICE TA819 - Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies. (Decision date - September 2022)

 DNP: NICE TA1089: (terminated appraisal) Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (Decision date September 2025)

Do Not Prescribe (DNP) Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again